secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001628280-24-046399
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma Q3 net loss $1.5M; Caldolor study, DMD designations announced
-------------------------------------------------------------------------------

- Q3 2024 net revenue $9.1M; net loss $1.5M ($0.11 loss per share); adjusted loss $0.26M ($0.02 per share).
- Real-world study of 150k patients shows Caldolor associated with fewer adverse drug reactions vs ketorolac.
- FDA grants Orphan Drug and Rare Pediatric Disease designations for ifetroban in Duchenne Muscular Dystrophy.
- Kristalose added to Medicaid plans in VA, LA, ME; Vibativ partner in Saudi Arabia begins ordering for launch.
- Phase II MENDING trial for delirium meets primary safety endpoint; CET plans pivotal study discussion with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024046399/0001628280-24-046399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828024046399/cpix-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer